Coreceptor-Based Hematopoietic Stem Cell Gene Therapy for HIV Disease

Area of Science:

• Virology
• Immunology
• Gene Therapy

Background:

• Combination antiretroviral therapy (cART) manages human immunodeficiency virus (HIV) but cannot eradicate it.
• HIV-1 entry relies on viral gp120 binding to CD4 and coreceptors CCR5 or CXCR4.
• Genetic resistance to HIV-1 exists, notably CCR5Δ32 homozygosity and certain CXCR4 mutants.

Purpose of the Study:

• To review advancements in coreceptor-based hematopoietic stem cell (HSC) gene therapy for HIV.
• To explore novel strategies for developing an HIV-resistant immune system via HSC modification.
• To present an alternative to lifelong cART for HIV patients.

Main Methods:

• Review of existing literature on HSC gene therapy targeting CCR5 and CXCR4.
• Analysis of natural coreceptor mutations conferring HIV resistance.
• Examination of the "Berlin patient" case as proof of concept for CCR5Δ32-modified HSC transplantation.

Main Results:

• Individuals with CCR5Δ32 deletion show significant resistance to HIV-1 infection.
• Naturally occurring CXCR4 mutants can reduce HIV-1 entry without compromising cellular function.
• Allogeneic stem cell transplantation from a CCR5Δ32 homozygous donor demonstrated successful HIV resistance.

Conclusions:

• Coreceptor-based HSC gene therapy is a promising strategy for achieving HIV resistance.
• Modification of CCR5 and CXCR4 on HSCs offers a pathway to an HIV-curative approach.
• Further research into HSC gene therapy strategies is crucial for overcoming indefinite HIV treatment.